CA2449247A1 — A method for treating inflammatory diseases by administering a ppar-delta agonist
Assigned to Merck and Co Inc · Expires 2002-12-19 · 23y expired
What this patent protects
A method for treating, controlling, preventing or reducing the risk of contracting an inflammatory disease or condition in a mammalian patient, comprises the steps of (1) selecting a patient in need thereof, and (2) treating the patient with a therapeutically effective amount of …
USPTO Abstract
A method for treating, controlling, preventing or reducing the risk of contracting an inflammatory disease or condition in a mammalian patient, comprises the steps of (1) selecting a patient in need thereof, and (2) treating the patient with a therapeutically effective amount of a composition comprising a PPAR-.delta. agonist. Inflammatory diseases that may be treated by this method include but are not limited to rheumatoid arthritis, juvenile rheumatoid arthritis, systemic lupus erythematosus, osteoarthritis, degenerative joint disease, one or more connective tissue diseases, ankylosing spondylitis, and bursitis.
Drugs covered by this patent
- Renacidin (CITRIC ACID) · Baxter
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.